v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Oct. 02, 2022
Dec. 31, 2021
Assets    
Cash and cash equivalents $ 1,298 $ 1,944
Short-term investments 34,825 29,125
Trade accounts receivable, less allowance for doubtful accounts: 2022—$474; 2021—$492 16,076 11,479
Inventories [1] 9,513 9,059
Current tax assets 2,544 4,266
Other current assets 6,149 3,820
Total current assets 70,403 59,693
Equity-method investments 9,826 16,472
Long-term investments 4,062 5,054
Property, plant and equipment, less accumulated depreciation: 2022—$14,931; 2021—$15,074 15,441 14,882
Identifiable intangible assets [2],[3] 28,151 25,146
Goodwill [4] 49,441 49,208
Noncurrent deferred tax assets and other noncurrent tax assets 7,136 3,341
Other noncurrent assets 10,890 7,679
Total assets 195,350 181,476
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2022—$2,566; 2021—$1,636 4,040 2,241
Trade accounts payable 6,267 5,578
Dividends payable 2,245 2,249
Income taxes payable 3,071 1,266
Accrued compensation and related items 2,852 3,332
Deferred revenues 6,191 3,067
Other current liabilities 19,647 24,939
Total current liabilities 44,314 42,671
Long-term debt 32,629 36,195
Pension benefit obligations 2,738 3,489
Postretirement benefit obligations 222 235
Noncurrent deferred tax liabilities 616 349
Other taxes payable 9,701 11,331
Other noncurrent liabilities 12,239 9,743
Total liabilities 102,459 104,013
Commitments and Contingencies
Common stock 476 473
Additional paid-in capital 91,359 90,591
Treasury stock (113,945) (111,361)
Retained earnings 122,967 103,394
Accumulated other comprehensive loss (8,225) (5,897)
Total Pfizer Inc. shareholders’ equity 92,631 77,201
Equity attributable to noncontrolling interests 259 262
Total equity 92,891 77,462
Total liabilities and equity $ 195,350 $ 181,476
[1] The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.
[2] The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see Note 2A), and for IPR&D, is partially offset by an impairment (see Note 4).
[3] The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.
[4] All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.